| 2000 til July |
Responsible Head for labile blood products |
| 1999 |
Prepare the contract with RBTS Lausanne for the infectious disease marker screening in Bern (ca. 35'000 donation
samples/year) |
| 1999 |
Pass the 2nd successive FDA inspection without citings (Form 483)
(after 1997) ! |
| 1999 |
Fuse the BTS ZLB with the RBTC to form the BTS Bern |
| 1998 |
Plan to implement HCV-PCR screening as of January 1999 BTS ZLB,
acquire 3rd party RBTS totalling about 2/3 of all blood donations in CH |
| 1997 |
Consolidate the Anti-D-Plasmapheresis-Program ZLB |
| 1997 |
Implement a new Blood Bank Software and reshaped work processes |
| 1996 |
Establish BTS ZLB as a part of the restructured BTS SRC |
| 1992 - 1995 |
Head AIS-Project: ex vivo-expansion of CD8-Tcells for therapy; plan,
build, and validate a laboratory for cell culture for human use; approved for clinical trials by Swiss regulatory authorities
(IKS) |
| 1994 |
Organise the Blood Transfusion Service ZLB (as of
October) |
| 1991 |
Implement HCV-PCR as an additional confirmation test
(ZLB) |
| 1990 |
Implement Anti-HCV-screening in Switzerland (BTS SRC, by 1 Aug), implement centralised confirmation procedure in Bern
(ZLB) |
| 1989 |
Implement ALAT-screening for the BTS SRC |
| since 1988 |
Expand the External Proficiency Scheme for the BTS SRC |
| 1988 |
Implement IQS (Internal Quality Standards) for ZLB-screening |
| 1988 |
Implement ALAT-screening for all blood donation
(ZLB) |
